EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Concurrent Administration of Triazoles with Chemotherapeutic and/or Immunosuppressant Agents Known to Have Moderate-to-Severe Drug-Drug Interactions in Patients with Hematologic Malignancies Hospitalized for Invasive Aspergillosis

Thomas J Walsh, Craig I Coleman, Melissa D Johnson, Belinda Lovelace, Barbara D Alexander

Mycopathologia · 2026

DOI: 10.1007/s11046-025-01043-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mycopathologia, 2026. Verfasst von Thomas J Walsh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Medicine and Microbiology & Immunology, University of Maryland School of Medicine, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Triazoles, Hematologic Neoplasms, Antifungal Agents, Immunosuppressive Agents. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: F2G, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Triazoles are widely used for treatment and prevention of invasive aspergillosis (IA) but can cause serious drug-drug interactions (DDIs) with chemotherapeutic (CT) and immunosuppressant (IS) agents via CYP3A4 inhibition. The frequency of triazole-CT or IS concurrent administration in hematologic malignancies (HM) patients newly admitted with IA is largely unknown.

Methods

We studied US IQVIA claims including adults with ≥ 1 claim for an inpatient stay with a diagnosis code for IA from October 1, 2015-November 30, 2022 and evidence of systemic antifungal therapy for ≥ 3 days during the hospitalization. The cohort was limited to patients with ≥ 1 HM diagnosis code within 6 months prior to IA admission. Utilization of triazoles with CT and/or ISs known to have moderate-to-severe pharmacokinetic (PK) interactions was described.

Results

Triazoles, predominantly isavuconazole (61.0%) and voriconazole (53.6%), were administered in 97.2% of 317 patients with IA. Of these, 241 (78.2%) received an interacting CT and/or IS. Potentially interacting agents administered with a triazole included corticosteroids (70.8%), calcineurin or mammalian target of rapamycin (mTOR) inhibitors (25.0%) (84.4% tacrolimus), alkylating agents (14.0%) (76.7% cyclophosphamide), venetoclax (9.7%), anthracyclines (6.2%), and vincristine (5.8%).

Conclusions

Concurrent administration of triazole with potential PK interactions with CT or IS agents occurred in most HM patients admitted for IA. Choosing alternative antifungals, therapeutic drug monitoring of triazoles or selective ISs, and dosage adjustment of CT/IS agents may mitigate the risk of adverse DDIs. New antifungal agents without serious DDIs with CT and/or IS agents are needed for treatment of IA to reduce the risk of serious adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriazolesHematologic NeoplasmsAntifungal AgentsImmunosuppressive AgentsAspergillosisAntineoplastic AgentsHumansDrug InteractionsFemaleMaleMiddle AgedAgedAdultHospitalizationInvasive Fungal InfectionsYoung Adult

Stichwörter der Autor:innen

AspergillosisChemotherapyDrug interactionsHematologic neoplasmsImmunosuppressive agentsTriazoles

Substanzen

TriazolesAntifungal AgentsImmunosuppressive AgentsAntineoplastic Agents

Autor:innen und Institutionen

  • Departments of Medicine and Microbiology & Immunology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Center for Innovative Therapeutics and Diagnostics, Richmond, VA, USA.
  • Department of Pharmacy Practice, School of Pharmacy, University of Connecticut, 69 North Eagleville Road, Unit 3092, Storrs, CT, 06269-3092, USA. craig.coleman@uconn.edu.
  • Infectious Diseases Division, Duke University, Durham, NC, USA.
  • Health Economics and Outcomes Research, F2G, Inc., Princeton, NJ, USA.

Förderung

  • F2G, Inc.

Zitieren

APA

Walsh, T. J., Coleman, C. I., Johnson, M. D., Lovelace, B., & Alexander, B. D. (2026). Concurrent Administration of Triazoles with Chemotherapeutic and/or Immunosuppressant Agents Known to Have Moderate-to-Severe Drug-Drug Interactions in Patients with Hematologic Malignancies Hospitalized for Invasive Aspergillosis. Mycopathologia. https://doi.org/10.1007/s11046-025-01043-4

Vancouver

Walsh TJ, Coleman CI, Johnson MD, Lovelace B, Alexander BD. Concurrent Administration of Triazoles with Chemotherapeutic and/or Immunosuppressant Agents Known to Have Moderate-to-Severe Drug-Drug Interactions in Patients with Hematologic Malignancies Hospitalized for Invasive Aspergillosis. Mycopathologia. 2026. doi:10.1007/s11046-025-01043-4

BibTeX
@article{Walsh2026,
  author = {Walsh, Thomas J and Coleman, Craig I and Johnson, Melissa D and Lovelace, Belinda and Alexander, Barbara D},
  title = {Concurrent Administration of Triazoles with Chemotherapeutic and/or Immunosuppressant Agents Known to Have Moderate-to-Severe Drug-Drug Interactions in Patients with Hematologic Malignancies Hospitalized for Invasive Aspergillosis},
  journal = {Mycopathologia},
  year = {2026},
  doi = {10.1007/s11046-025-01043-4}
}
Kostenlos starten →